Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Translating the Manufacture of Immunotherapeutic PLGA Nanoparticles from Lab to Industrial Scale: Process Transfer and In Vitro Testing

MC. Operti, A. Bernhardt, J. Pots, V. Sincari, E. Jager, S. Grimm, A. Engel, A. Benedikt, M. Hrubý, IJM. De Vries, CG. Figdor, O. Tagit

. 2022 ; 14 (8) : . [pub] 20220813

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22023536

Grant support
686089 European Union
Spinoza grant Dutch Research Council - Netherlands
269019 ERC Advanced Grant Pathfinder
2009-4402 Dutch cancer society award

Poly(lactic-co-glycolic acid) (PLGA) nanoparticle-based drug delivery systems are known to offer a plethora of potential therapeutic benefits. However, challenges related to large-scale manufacturing, such as the difficulty of reproducing complex formulations and high manufacturing costs, hinder their clinical and commercial development. In this context, a reliable manufacturing technique suitable for the scale-up production of nanoformulations without altering efficacy and safety profiles is highly needed. In this paper, we develop an inline sonication process and adapt it to the industrial scale production of immunomodulating PLGA nanovaccines developed using a batch sonication method at the laboratory scale. The investigated formulations contain three distinct synthetic peptides derived from the carcinogenic antigen New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) together with an invariant natural killer T-cell (iNKT) activator, threitolceramide-6 (IMM60). Process parameters were optimized to obtain polymeric nanovaccine formulations with a mean diameter of 150 ± 50 nm and a polydispersity index <0.2. Formulation characteristics, including encapsulation efficiencies, release profiles and in vitro functional and toxicological profiles, are assessed and statistically compared for each formulation. Overall, scale-up formulations obtained by inline sonication method could replicate the colloidal and functional properties of the nanovaccines developed using batch sonication at the laboratory scale. Both types of formulations induced specific T-cell and iNKT cell responses in vitro without any toxicity, highlighting the suitability of the inline sonication method for the continuous scale-up of nanomedicine formulations in terms of efficacy and safety.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22023536
003      
CZ-PrNML
005      
20221031095257.0
007      
ta
008      
221010s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/pharmaceutics14081690 $2 doi
035    __
$a (PubMed)36015316
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Operti, Maria Camilla $u Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands $u Evonik Operations GmbH, Research Development & Innovation, 64293 Darmstadt, Germany $1 0000000222176096
245    10
$a Translating the Manufacture of Immunotherapeutic PLGA Nanoparticles from Lab to Industrial Scale: Process Transfer and In Vitro Testing / $c MC. Operti, A. Bernhardt, J. Pots, V. Sincari, E. Jager, S. Grimm, A. Engel, A. Benedikt, M. Hrubý, IJM. De Vries, CG. Figdor, O. Tagit
520    9_
$a Poly(lactic-co-glycolic acid) (PLGA) nanoparticle-based drug delivery systems are known to offer a plethora of potential therapeutic benefits. However, challenges related to large-scale manufacturing, such as the difficulty of reproducing complex formulations and high manufacturing costs, hinder their clinical and commercial development. In this context, a reliable manufacturing technique suitable for the scale-up production of nanoformulations without altering efficacy and safety profiles is highly needed. In this paper, we develop an inline sonication process and adapt it to the industrial scale production of immunomodulating PLGA nanovaccines developed using a batch sonication method at the laboratory scale. The investigated formulations contain three distinct synthetic peptides derived from the carcinogenic antigen New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) together with an invariant natural killer T-cell (iNKT) activator, threitolceramide-6 (IMM60). Process parameters were optimized to obtain polymeric nanovaccine formulations with a mean diameter of 150 ± 50 nm and a polydispersity index &lt;0.2. Formulation characteristics, including encapsulation efficiencies, release profiles and in vitro functional and toxicological profiles, are assessed and statistically compared for each formulation. Overall, scale-up formulations obtained by inline sonication method could replicate the colloidal and functional properties of the nanovaccines developed using batch sonication at the laboratory scale. Both types of formulations induced specific T-cell and iNKT cell responses in vitro without any toxicity, highlighting the suitability of the inline sonication method for the continuous scale-up of nanomedicine formulations in terms of efficacy and safety.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bernhardt, Alexander $u Evonik Operations GmbH, Research Development & Innovation, 64293 Darmstadt, Germany
700    1_
$a Pots, Jeanette $u Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands
700    1_
$a Sincari, Vladimir $u Institute of Macromolecular Chemistry CAS, Heyrovsky Square 2, 162 06 Prague, Czech Republic $1 000000027379066X
700    1_
$a Jager, Eliezer $u Institute of Macromolecular Chemistry CAS, Heyrovsky Square 2, 162 06 Prague, Czech Republic $1 0000000199392355
700    1_
$a Grimm, Silko $u Evonik Operations GmbH, Research Development & Innovation, 64293 Darmstadt, Germany
700    1_
$a Engel, Andrea $u Evonik Corporation, Birmingham Laboratories, Birmingham, AL 35211, USA
700    1_
$a Benedikt, Anne $u Evonik Operations GmbH, Research Development & Innovation, 64293 Darmstadt, Germany
700    1_
$a Hrubý, Martin $u Institute of Macromolecular Chemistry CAS, Heyrovsky Square 2, 162 06 Prague, Czech Republic $1 000000025075261X
700    1_
$a De Vries, Ingrid Jolanda M $u Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands $1 0000000286534040
700    1_
$a Figdor, Carl G $u Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands
700    1_
$a Tagit, Oya $u Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands $1 0000000257736647
773    0_
$w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 14, č. 8 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36015316 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20221010 $b ABA008
991    __
$a 20221031095255 $b ABA008
999    __
$a ind $b bmc $g 1853909 $s 1174824
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 14 $c 8 $e 20220813 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
GRA    __
$a 686089 $p European Union
GRA    __
$a Spinoza grant $p Dutch Research Council $2 Netherlands
GRA    __
$a 269019 $p ERC Advanced Grant Pathfinder
GRA    __
$a 2009-4402 $p Dutch cancer society award
LZP    __
$a Pubmed-20221010

Find record

Citation metrics

Archiving options